Articles published in the press
EvaluatePharma, September 9, 2011
Aprea Secures Funding for Further Development of the AntiCancer Compound APR-246
EUROINVESTOR.co.uk, February 23, 2011
Aprea reports completion of the Phase I/II safety study with APR-246 in cancer patients
The "new" prostate cancer infolink, December 5, 2010
Unexpected discovery of new investigational drug for mCRPC
SwedenBIO, November 8, 2010
Aprea to Present Preclinical Data about APR-246 at the American Society of Hematology Annual Meeting, in Orlando, USA
SwedenBIO, September 30, 2010
Ulf Björklund New CEO at Aprea
121.nu, September 30, 2010
Ulf Björklund – ny VD på Aprea AB
EvaluatePharma, August 27, 2010
Aprea Will Attend the BIO Japan 2010 World Business Forum, Sept 29 - Oct 1
THE MEDICAL NEWS, May 19, 2010
Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting
STOCK Nod, May 18, 2010
Aprea to Present Phase I/II Trial Design
EUROINVESTOR.se, May 18, 2010
Aprea presenterar design av klinisk fas I/II-studie
Chemicalnet.se, March 31, 2010
De får Forska&Väx-pengar
EvaluatePharma, March 30, 2010
Aprea AB Receives Funding from VINNOVA, March 30
BiotechSweden, March 30, 2010
11 miljoner till life science-bolag
BolagsFakta.se, March 30, 2010
VINNOVA finansierar 45 småföretag med 48 miljoner kronor
Pharma Online nyhetsbrev, February 19, 2010
Apreas cancerprodukt rekommenderat orphan drug-status
SwedenBIO, February 18, 2010
APREA: The European Medicines Agency recommends Orphan Drug Designation for APR-246 in Acute Myeloid Leukemia
Webfinanser, February 18, 2010
APREA: Den europeiska läkemedelsmyndigheten, EMA, rekommenderar särläkemedelsstatus för APR-246 för akut myeloid leukemi
Pharmaceutical Business Review, February 18, 2010
Aprea's Treatment For AML Gets Orphan Drug Status From EMEA
Pharmajobs, February 18, 2010
AML candidate recommended for orphan status
MedIndia, February 18, 2010
Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
EUROINVESTOR, February 18, 2010
Karolinska Development: EMEA Rekommenderar Särläkemedelsstatus för Behandling av Akut Myeloisk Leukemi
The Medical News, February 18, 2010
Aprea's AML treatment receives EMEA recommendation for orphan drug status
Biotech Intelligence, December 3, 2009
Aprea to Present Preclinical Data and an Update From the Clinical PhaseI/IIa Cancer Study on APR-246 at the American Society of Hematology Annual Meeting in New Orleans, USA
Evaluate Pharma, November 25, 2009
Aprea AB Receives Allowance of a Key Patent in US and Europe
Evaluate Pharma, November 10, 2009
Aprea Attended the BIO-Europe 2009 Meeting in Vienna, Austria, November 2-4
Stockholm Uppsala Life Science, June 3, 2009
APREA’S DRUG CANDIDATE FOR CLINICAL TRIALS
di.se Dagens Industri, May 26, 2009
Svenskt bolag testar nytt cancerpreparat
Biotech Sweden, May 15, 2009
Klartecken för ny cancerstudie
SwedenBIO, May 14, 2009
Swedish Medical Products Agency approves start of Phase I clinical trial with APR-246, the anticancer candidate of Aprea
Chemicalnet.se, May 14, 2009
Apreas cancerläkemedel till klinik
Webfinanser, May 14, 2009
Läkemedelsverket godkänner klinisk prövning av Apreas läkemedelskandidat mot cancer
Industrifonden, May 14, 2009
Aprea får starta klinisk prövning av nytt läkemedel mot cancer
Biotech Scandinavia, May 13, 2009
Nya tumördödande molekyler funna
Thaindian News, February 28, 2009
Scientists identify gene that plays key role in cancer
Science Daily, February 27, 2009
Newly Discovered Gene Plays Vital Role In Cancer
Biotech Sweden, February 27, 2009
Nyupptäckt gen stoppar anticancerprotein
Göteborgs-Posten, February 26, 2009
Ny cancergen upptäckt
Future by Semcon, December, 2008
Nyckeln till cancerns gåta?
Oncology Times, October 25, 2008
Breast Cancer: DoD 'Era of Hope' Meeting Spotlights Promising Treatment, Imaging, & Vaccines
Biotech Sweden, September 8, 2008
Aprea changes its team
Reuters, July 1, 2008
New targeted treatment promising in breast cancer
Biotech Sweden, May 20, 2008
April saw new Aprea CEO
Reuters, April 14, 2008
Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential...
Real Deals Europe, November 15, 2007
Aprea raises SKr50m for cancer drug development
Insider News, November 15, 2007
Industrifonden steps up a gear
Chemicalnet.se, November 9, 2007
25 miljoner till nytt cancerläkemedel
Biotech Sweden, November 8, 2007
Industrifonden in on cancer drug
Science Business, November 7, 2007
Swedish pharma start-up receives SEK25M for cancer drug
E24 Näringsliv, November 6, 2007
Svensk cancermedicin lockar storinvesterare
Ny Teknik, November 6, 2007
Svensk cancermedicin lagar kroppens eget skydd
jnytt.se, November 6, 2007
Industrifonden investerar i nytt cancerläkemedel
Global Information, Inc., May, 2005
Apoptosis: Promise or Deception?
|
